CoChat

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH

Open access

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

UNLABELLED: NAFLD is the most common liver disease worldwide but it is the potential evolution to NASH and eventually to hepatocellular carcinoma (HCC), even in the absence of cirrhosis, that makes NAFLD of such clinical importance. AIM: we aimed to create a mouse model reproducing the pathological spectrum of NAFLD and to investigate the role of possible co-factors in promoting HCC. METHODS: mice were treated with a choline-deficient L-amino-acid-defined-diet (CDAA) or its control (CSAA diet) and subjected to a low-dose i.p. injection of CCl4 or vehicle. Insulin resistance was measured by the euglycemic-hyperinsulinemic clamp method. Steatosis, fibrosis and HCC were evaluated by histological and molecular analysis. RESULTS: CDAA-treated mice showed peripheral insulin resistance at 1 month. At 1-3 months, extensive steatosis and fibrosis were observed in CDAA and CDAA+CCl4 groups. At 6 months, equal increase in steatosis and fibrosis was observed between the two groups, together with the appearance of tumor. At 9 months of treatment, the 100% of CDAA+CCl4 treated mice revealed tumor versus 40% of CDAA mice. Insulin-like Growth Factor-2 (IGF-2) and Osteopontin (SPP-1) were increased in CDAA mice versus CSAA. Furthermore, Immunostaining for p-AKT, p-c-Myc and Glypican-3 revealed increased positivity in the tumors. CONCLUSIONS: the CDAA model promotes the development of HCC from NAFLD-NASH in the presence of insulin resistance but in the absence of cirrhosis. Since this condition is increasingly recognized in humans, our study provides a model that may help understanding mechanisms of carcinogenesis in NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0097136

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effect of diet treatment on metabolic parameters and body weight. A–B) Mice treated with CDAA diet for 1 month develop peripheral insulin resistance as shown by the lower glucose uptake vs CSAA-treated mice (M value) with similar levels of FPG. CCl4 treatment induces an increase in fasting plasma glucose and enhances the condition of insulin resistance, reducing M value. C) Insulin levels measured at 1 month of treatment. D) The graphic shows a gradual increase in body weight in both CDAA and CSAA diet. CCl4 injection similarly reduces body weight in both diets. E) Epididymal fat/body weight ratio appears to be similar between the two different diets both at 3 and 9 months of treatment, with similar reduction in the presence of CCl4. Data represent mean ± SD; §p<0.05 vs CSAA; ù p<0.05 vs CDAA; *p<0.05 vs CSAA 3 months; #p<0.05 vs CSAA+CCl4 3 months; ò p<0.05 vs CDAA 3 months; ç p<0.05 vs CDAA+CCl4 3 months; b p<0.05 vs CSAA+CCl4 6 months; c p<0.05 vs CSAA+CCl4 9 months; d p<0.05 vs CSAA.
Figure 1 Effect of diet treatment on metabolic parameters and body weight. A–B) Mice treated with CDAA diet for 1 month develop peripheral insulin resistance as shown by the lower glucose uptake vs CSAA-treated mice (M value) with similar levels of FPG. CCl4 treatment induces an increase in fasting plasma glucose and enhances the condition of insulin resistance, reducing M value. C) Insulin levels measured at 1 month of treatment. D) The graphic shows a gradual increase in body weight in both CDAA and CSAA diet. CCl4 injection similarly reduces body weight in both diets. E) Epididymal fat/body weight ratio appears to be similar between the two different diets both at 3 and 9 months of treatment, with similar reduction in the presence of CCl4. Data represent mean ± SD; §p<0.05 vs CSAA; ù p<0.05 vs CDAA; *p<0.05 vs CSAA 3 months; #p<0.05 vs CSAA+CCl4 3 months; ò p<0.05 vs CDAA 3 months; ç p<0.05 vs CDAA+CCl4 3 months; b p<0.05 vs CSAA+CCl4 6 months; c p<0.05 vs CSAA+CCl4 9 months; d p<0.05 vs CSAA.CC BY · PubMed Central
Figure 2 Treatment with CDAA determines a progressive increase of hepatic steatosis. A) Increased levels of liver/body weight fraction are observed in the group of mice treated with CDAA diet, either with or without CCl4 administration, in comparison to mice treated with control diet, starting at 1 month. B) Histochemical staining and relative morphometric evaluation for Oil Red O and C) hepatic triglyceride measurement show increased deposition of lipids in the liver parenchyma of CDAA and CDAA+CCl4 treated animals in comparison to CSAA treated mice. Data represent mean ± SD; ò p<0.05 vs CSAA 1 month; *p<0.05 vs CSAA 3 months; §p<0.05 vs CSAA 6 months; #p<0.05 vs CSAA 9 months; ç p<0.05 vs CDAA 6 months; ù p<0.05 vs CDAA 9 months.
Figure 2 Treatment with CDAA determines a progressive increase of hepatic steatosis. A) Increased levels of liver/body weight fraction are observed in the group of mice treated with CDAA diet, either with or without CCl4 administration, in comparison to mice treated with control diet, starting at 1 month. B) Histochemical staining and relative morphometric evaluation for Oil Red O and C) hepatic triglyceride measurement show increased deposition of lipids in the liver parenchyma of CDAA and CDAA+CCl4 treated animals in comparison to CSAA treated mice. Data represent mean ± SD; ò p<0.05 vs CSAA 1 month; *p<0.05 vs CSAA 3 months; §p<0.05 vs CSAA 6 months; #p<0.05 vs CSAA 9 months; ç p<0.05 vs CDAA 6 months; ù p<0.05 vs CDAA 9 months.CC BY · PubMed Central
Figure 3 Gene expression of elements involved in carbohydrate and lipid metabolism. qRT-PCR expression shows a progressive decrease of the amount of PEPCK (A), G6Pase (B), ChREBP (D), ACOX-1 (E) and CPT1A (F) mRNA expression in the groups of CDAA or CDAA+ CCl4, while only a slight decrease is observed for mRNA expression of SREBP-1c (C). Data represent mean ± SD; ò p<0.05 vs CSAA 1 month; *p<0.05 vs CSAA 3 months; §p<0.05 vs CSAA 6 months; #p<0.05 vs CSAA 9 months; ç p<0.05 vs CDAA 6 months; ù p<0.05 vs CDAA 9 months.
Figure 3 Gene expression of elements involved in carbohydrate and lipid metabolism. qRT-PCR expression shows a progressive decrease of the amount of PEPCK (A), G6Pase (B), ChREBP (D), ACOX-1 (E) and CPT1A (F) mRNA expression in the groups of CDAA or CDAA+ CCl4, while only a slight decrease is observed for mRNA expression of SREBP-1c (C). Data represent mean ± SD; ò p<0.05 vs CSAA 1 month; *p<0.05 vs CSAA 3 months; §p<0.05 vs CSAA 6 months; #p<0.05 vs CSAA 9 months; ç p<0.05 vs CDAA 6 months; ù p<0.05 vs CDAA 9 months.CC BY · PubMed Central
Figure 4 Treatment with CDAA or CDAA+CCl4 induces hepatic inflammation in mice. A) Immunohistochemistry for pan-macrophage marker F4/80. B) TNFα and (C) MCP-1 mRNA levels are increased in CDAA or CDAA+ CCl4 already after 1 month of treament. D–F) Markers of Inflammasome activation ASC, Caspase-1 and IL-1β show increased expression in CDAA or CDAA+ CCl4 groups. Data represent mean ± SD; ò p<0.05 vs CSAA 1 month; *p<0.05 vs CSAA 3 months; §p<0.05 vs CSAA 6 months; #p<0.05 vs CSAA 9 months; ç p<0.05 vs CDAA 6 months; ù p<0.05 vs CDAA 9 months.
Figure 4 Treatment with CDAA or CDAA+CCl4 induces hepatic inflammation in mice. A) Immunohistochemistry for pan-macrophage marker F4/80. B) TNFα and (C) MCP-1 mRNA levels are increased in CDAA or CDAA+ CCl4 already after 1 month of treament. D–F) Markers of Inflammasome activation ASC, Caspase-1 and IL-1β show increased expression in CDAA or CDAA+ CCl4 groups. Data represent mean ± SD; ò p<0.05 vs CSAA 1 month; *p<0.05 vs CSAA 3 months; §p<0.05 vs CSAA 6 months; #p<0.05 vs CSAA 9 months; ç p<0.05 vs CDAA 6 months; ù p<0.05 vs CDAA 9 months.CC BY · PubMed Central
Figure 5 Treatment with CDAA or CDAA+CCl4 induces liver injury and expression of markers of hepatic fibrogenesis in mice. A) The total degree of liver injury (hepatic steatosis and necroinflammation) was determined according to the NAS score. B) The number of apoptotic cells was measured with TUNEL and expressed as apoptotic cell/field. C–E) qRT-PCR shows a progressive increase, in a time dependent manner, of the amount of TIMP-1 (C), CTGF (D) and TGFβ (E) mRNA expression in the group of CDAA, with the evidence of a promoting effect exerted by CCl4 starting from month 3. Data represent mean ± SD; ò p<0.05 vs CSAA 1 month; *p<0.05 vs CSAA 3 months; §p<0.05 vs CSAA 6 months; #p<0.05 vs CSAA 9 months; ç p<0.05 vs CDAA 6 months; ù p<0.05 vs CDAA 9 months.
Figure 5 Treatment with CDAA or CDAA+CCl4 induces liver injury and expression of markers of hepatic fibrogenesis in mice. A) The total degree of liver injury (hepatic steatosis and necroinflammation) was determined according to the NAS score. B) The number of apoptotic cells was measured with TUNEL and expressed as apoptotic cell/field. C–E) qRT-PCR shows a progressive increase, in a time dependent manner, of the amount of TIMP-1 (C), CTGF (D) and TGFβ (E) mRNA expression in the group of CDAA, with the evidence of a promoting effect exerted by CCl4 starting from month 3. Data represent mean ± SD; ò p<0.05 vs CSAA 1 month; *p<0.05 vs CSAA 3 months; §p<0.05 vs CSAA 6 months; #p<0.05 vs CSAA 9 months; ç p<0.05 vs CDAA 6 months; ù p<0.05 vs CDAA 9 months.CC BY · PubMed Central
Figure 6 Treatment with CDAA or CDAA+CCl4 induces hepatic fibrosis in mice. A–B) qRT-PCR expression shows a progressive increase, in a time dependent manner, of the amount of Collagen α1(I) (A) and αSMA (B) mRNA in the group of CDAA, with the evidence of a promoting effect exerted by CCl4 starting from month 6. Conversely, mice treated with control diet (CSAA) do not show any time-dependent increase neither in the level of Collagen α1(I) nor of αSMA, not even after chronic CCl4 injection. C–D) Morphometric analysis shows increased collagen deposition by Sirius Red staining (C) and increased HSC activation by αSMA Immunohistochemistry (D) in the liver of CDAA treated mice in comparison to CSAA treated mice. This condition is even enhanced in the liver of mice treated with CDAA+CCl4. Data represent mean ± SD; *p<0.05 vs CSAA; #p<0.05 vs CSAA+ CCl4; ò p<0.05 vs CDAA.
Figure 6 Treatment with CDAA or CDAA+CCl4 induces hepatic fibrosis in mice. A–B) qRT-PCR expression shows a progressive increase, in a time dependent manner, of the amount of Collagen α1(I) (A) and αSMA (B) mRNA in the group of CDAA, with the evidence of a promoting effect exerted by CCl4 starting from month 6. Conversely, mice treated with control diet (CSAA) do not show any time-dependent increase neither in the level of Collagen α1(I) nor of αSMA, not even after chronic CCl4 injection. C–D) Morphometric analysis shows increased collagen deposition by Sirius Red staining (C) and increased HSC activation by αSMA Immunohistochemistry (D) in the liver of CDAA treated mice in comparison to CSAA treated mice. This condition is even enhanced in the liver of mice treated with CDAA+CCl4. Data represent mean ± SD; *p<0.05 vs CSAA; #p<0.05 vs CSAA+ CCl4; ò p<0.05 vs CDAA.CC BY · PubMed Central
Figure 7 Treatment with CDAA+CCl4 induces development of HCC after 9 months. A) Mice sacrificed after 1 and 3 months from the beginning of the treatment do not show any nodular lesions in the parenchyma. Conversely, mice sacrificed after 6 months of treatment show few nodular lesions compatible with HCC. After 9 months of treatment mice show a liver parenchyma completely damaged. B) Histochemical staining for H&E and Sirius Red show respectively no fat deposition and absence of collagen content into the nodules. C) After 6 months of treatment, about 30% of mice show HCC development both with CDAA and CDAA+CCl4. After 9 months of treatment, 100% of mice from the CDAA+CCl4 group show at least one nodule into the liver parenchyma. D) After 6 months, the average of nodules dimension in the group of CDAA mice is significantly lower in comparison to that of the group of CDAA+CCl4 mice. After 9 months, the average of nodules dimension in the group of CDAA+CCl4 mice results of 9 mm, in comparison to 3 mm of the group of mice treated with CDAA alone. Data represent mean ± SD; *p<0.05 vs CDAA.
Figure 7 Treatment with CDAA+CCl4 induces development of HCC after 9 months. A) Mice sacrificed after 1 and 3 months from the beginning of the treatment do not show any nodular lesions in the parenchyma. Conversely, mice sacrificed after 6 months of treatment show few nodular lesions compatible with HCC. After 9 months of treatment mice show a liver parenchyma completely damaged. B) Histochemical staining for H&E and Sirius Red show respectively no fat deposition and absence of collagen content into the nodules. C) After 6 months of treatment, about 30% of mice show HCC development both with CDAA and CDAA+CCl4. After 9 months of treatment, 100% of mice from the CDAA+CCl4 group show at least one nodule into the liver parenchyma. D) After 6 months, the average of nodules dimension in the group of CDAA mice is significantly lower in comparison to that of the group of CDAA+CCl4 mice. After 9 months, the average of nodules dimension in the group of CDAA+CCl4 mice results of 9 mm, in comparison to 3 mm of the group of mice treated with CDAA alone. Data represent mean ± SD; *p<0.05 vs CDAA.CC BY · PubMed Central
Figure 8 The expression of pro-carcinogenic genes is modified already after 3 months of treatment. A) Immunohistochemistry for p-AKT and p-c-Myc shows positive staining in the liver parenchyma of CDAA+CCl4 mice, in correspondence of HCC foci (20X magnification) B) Glypican-3 Immunohistochemistry shows positive staining in the tumor area (5X and 20X magnification). C) Mice treated with CDAA or CDAA+CCl4 show, starting at 3 months, increased levels of mRNA for IGF-2 and (D) SPP-1 and (E) decreased mRNA levels of PTEN. Data represent mean ± SD; *p<0.05 vs CSAA; #p<0.05 vs CSAA+CCl4.
Figure 8 The expression of pro-carcinogenic genes is modified already after 3 months of treatment. A) Immunohistochemistry for p-AKT and p-c-Myc shows positive staining in the liver parenchyma of CDAA+CCl4 mice, in correspondence of HCC foci (20X magnification) B) Glypican-3 Immunohistochemistry shows positive staining in the tumor area (5X and 20X magnification). C) Mice treated with CDAA or CDAA+CCl4 show, starting at 3 months, increased levels of mRNA for IGF-2 and (D) SPP-1 and (E) decreased mRNA levels of PTEN. Data represent mean ± SD; *p<0.05 vs CSAA; #p<0.05 vs CSAA+CCl4.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 98

Metadata

Authors
De Minicis, S., Agostinelli, L., Rychlicki, C., Sorice, G. P., Saccomanno, S., Candelaresi, C., Giaccari, A., Trozzi, L., Pierantonelli, I., Mingarelli, E., Marzioni, M., Muscogiuri, G., Gaggini, M., Benedetti, A., Gastaldelli, A., Guido, M., & Svegliati-Baroni, G.
Affiliations
  • Marche Polytechnic University (IT)
  • Università Cattolica del Sacro Cuore (IT)
  • Istituto di Fisiologia Clinica (IT)
  • University of Padua (IT)
Venue
PLoS ONE
Published
2014-05-22
Volume
9
Issue
5
Pages
e97136
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2086542332
Cited by
97
References
53
Citations by year
2026: 1 · 2025: 6 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 10 · 2020: 16 · 2019: 12 · 2018: 12 · 2017: 7 · 2016: 6 · 2015: 5 · 2014: 1
FWCI
4.79
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
Funders
  • European Commission (241762)
  • Ministero della Salute (GR-2010, GR-2010-2306996)
  • Ministero dell’Istruzione, dell’Università e della Ricerca (2007–2013, PRIN 2009, FIRB2010, 2009X84L84_003)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
hepatocellular carcinoma, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, peripheral insulin resistance, choline-deficient L-amino acid-defined diet, carbon tetrachloride, liver fibrosis, hepatic steatosis, insulin-like growth factor II, osteopontin, Akt phosphorylation, c-Myc, glypican-3, hepatocarcinogenesis, mouse model
MeSH terms
Age Factors, Animals, Choline Deficiency, Disease Models, Animal, Food, Formulated, Carcinoma, Hepatocellular, Insulin Resistance, Insulin-Like Growth Factor II, Liver Neoplasms, Proto-Oncogene Proteins c-myc, Mice, Osteopontin, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.